PTIX PROTAGENIC THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PROTAGENIC THERAPEUTICS INC reported revenue of n/a, net income of −$964K and diluted EPS of −$0.53; for the fiscal year ended March 2026 revenue was $0.
PTIX annual revenue and earnings
- Fiscal year ended Mar 2026: revenue $0, gross profit n/a, operating income −$4.50M, net income $1.37M (margin n/a), EPS $0.59
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$5.70M, net income −$5.53M (margin n/a), EPS −$1.13
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$4.53M, net income −$5.00M (margin n/a), EPS −$1.15
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$3.56M, net income −$3.56M (margin n/a), EPS −$0.82
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$4.14M, net income −$4.52M (margin n/a), EPS −$0.31
PTIX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$964K, EPS −$0.53
- Quarter ended Mar 31, 2026 (from the annual report): revenue n/a, net income $5.08M, EPS $1.29
- Quarter ended Dec 31, 2025: revenue n/a, net income $2.21M, EPS $1.14
- Quarter ended Sep 30, 2025: revenue n/a, net income −$869K, EPS −$0.47
- Quarter ended Jun 30, 2025: revenue $0, net income −$5.06M, EPS −$1.37
- Quarter ended Mar 31, 2025: revenue $0, net income −$1.44M, EPS −$2.75
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$850K, EPS −$0.16
- Quarter ended Sep 30, 2024: revenue $0, net income −$582K, EPS −$0.11
- Quarter ended Jun 30, 2024: revenue $0, net income −$324K, EPS −$0.06
- Quarter ended Mar 31, 2024: revenue $0, net income −$1.72M, EPS −$5.44
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$1.68M, EPS −$0.38
- Quarter ended Sep 30, 2023: revenue $0, net income −$1.40M, EPS −$0.32
- Quarter ended Jun 30, 2023: revenue $0, net income −$1.21M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue $0, net income −$718K, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$601K, EPS n/a
- Quarter ended Sep 30, 2022: revenue $0, net income −$925K, EPS −$0.21
- Quarter ended Jun 30, 2022: revenue $0, net income −$667K, EPS −$0.15
- Quarter ended Mar 31, 2022: revenue $0, net income −$1.36M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$890K, EPS −$0.04
- Quarter ended Sep 30, 2021: revenue n/a, net income −$878K, EPS −$0.05
PTIX cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow −$2.81M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.22M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$3.70M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.99M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$2.80M, share buybacks n/a
PTIX balance sheet
- Jun 30, 2026: cash n/a, total assets $2.80M, total liabilities $1.07M, shareholders' equity $1.72M
- Mar 31, 2026: cash n/a, total assets $3.65M, total liabilities $1.03M, shareholders' equity $2.62M
- Dec 31, 2025: cash n/a, total assets $4.43M, total liabilities $6.82M, shareholders' equity −$2.39M
- Sep 30, 2025: cash n/a, total assets $5.00M, total liabilities $9.70M, shareholders' equity −$4.70M
- Jun 30, 2025: cash n/a, total assets $6.49M, total liabilities $10.5M, shareholders' equity −$3.97M
- Mar 31, 2025: cash n/a, total assets $89.1K, total liabilities $5.04M, shareholders' equity −$4.95M
- Dec 31, 2024: cash n/a, total assets $1.96M, total liabilities $943K, shareholders' equity −$3.32M
- Sep 30, 2024: cash n/a, total assets $1.51M, total liabilities $789K, shareholders' equity −$2.47M
What is PTIX's revenue?
PROTAGENIC THERAPEUTICS INC reported $0 of revenue for the fiscal year ended March 2026.
Is PTIX profitable?
Yes. PROTAGENIC THERAPEUTICS INC earned $5.46M over the last four quarters.
What is PTIX's EPS?
Diluted earnings per share over the last four quarters were $1.43; −$0.53 in the latest quarter.